Shares will be much higher in comings weeks and months as the company gets ready to start the phase III trial for Firdapse. Firdapse should pass easily because it is already approved and selling in Europe.
The big unknown is the price that BioMarin is going to pay for the balance of CPRX stock so they can own CPP115. CPP115 will be a mega blockbuster.
"BioMarin is a very successful orphan drug developer that understands this space very well and the fact that they invested $5,000,000 in Catalyst for 17% ownership reflects their confidence in not only Firdapse, but in Catalyst."